Recombinant Anti-EGFR × Anti-FcγRIII Bispecific Antibody (CrossMab) has been generated by applying the Crossmab format to generate an IgG shaped entity that binds each ligand with one arm. This BsAb is capable of targeting the tumor and recruiting NK effector cells via binding to the FcγRIII of the NK cells. It was designed for the treatment of renal cell carcinoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.